Cargando…

维布妥昔单抗治疗CD30阳性淋巴瘤的研究进展

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067377/
https://www.ncbi.nlm.nih.gov/pubmed/36987732
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.01.018
_version_ 1785018453444263936
collection PubMed
description
format Online
Article
Text
id pubmed-10067377
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-100673772023-04-04 维布妥昔单抗治疗CD30阳性淋巴瘤的研究进展 Zhonghua Xue Ye Xue Za Zhi 综述 Editorial office of Chinese Journal of Hematology 2023-01 /pmc/articles/PMC10067377/ /pubmed/36987732 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.01.018 Text en 2023年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License.
spellingShingle 综述
维布妥昔单抗治疗CD30阳性淋巴瘤的研究进展
title 维布妥昔单抗治疗CD30阳性淋巴瘤的研究进展
title_full 维布妥昔单抗治疗CD30阳性淋巴瘤的研究进展
title_fullStr 维布妥昔单抗治疗CD30阳性淋巴瘤的研究进展
title_full_unstemmed 维布妥昔单抗治疗CD30阳性淋巴瘤的研究进展
title_short 维布妥昔单抗治疗CD30阳性淋巴瘤的研究进展
title_sort 维布妥昔单抗治疗cd30阳性淋巴瘤的研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067377/
https://www.ncbi.nlm.nih.gov/pubmed/36987732
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.01.018
work_keys_str_mv AT wéibùtuǒxīdānkàngzhìliáocd30yángxìnglínbāliúdeyánjiūjìnzhǎn
AT wéibùtuǒxīdānkàngzhìliáocd30yángxìnglínbāliúdeyánjiūjìnzhǎn
AT wéibùtuǒxīdānkàngzhìliáocd30yángxìnglínbāliúdeyánjiūjìnzhǎn